Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

PropThink: NBY Milestone From Galderma Confirms Key Trial Moving Forward

By R&D Editors | September 26, 2012

By David Moskowitz

Novabay Pharmaceuticals (AMEX:NBY) could trade up today after the company announced the receipt of a $2.6M milestone payment from its development and marketing partner, Galderma S.A., a leading pharmaceutical company focused on the dermatology segment. The milestone is related to the clinical advancement of NVC-422, a novel anti-infective in development with Galderma for the topical treatment of impetigo. Impetigo is a highly contagious skin infection that can become deadly when caused by methcillin-resistant Staph aureus (MRSA). Given the recent trend for higher rates of MRSA in the U.S.  and increasing resistance to current topical treatments like Bactroban ointment and cream, the need for new treatments is high. Galderma, a private venture between L’Oreal and Nestle, books over $1 billion in annual revenues, and as a leader in the dermatology segment, adds significant credibility to the NVC-422 program. The milestone payment announced today indicates that the compound is moving closer to commercialization.

While NBY lists the impetigo program with Galderma as Phase II on its website, the current clinical trial was upsized earlier this year, and could provide pivotal results such that Galderma could apply to the FDA for approval once the study is completed. Under terms of the licensing agreement, Galderma is responsible for the ongoing clinical development of NVC-422 for impetigo and other indications, and NovaBay is entitled to escalating double-digit royalties on net product sales, if NVC-422 is commercialized. Galderma has marketing rights to the compound in most major global markets, and NovaBay retained rights in certain Asian markets. The company also has rights to promote the drug in hospitals and other healthcare institutions in North America. NBY shares are way off their highs this year, when the Galderma trial was pushed back so that the study could be designed for more patients. Expect NBY to climb back to those highs with this trial now on track to report out next year.

To see this article in its original form, click here.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: PropThink via Thomson Reuters ONE

HUG#1643792

Related Articles Read More >

5 R&D developments to keep an eye on this week: Solar crash and Trump’s energy pivot meets Musk’s rebellion
Mayo Clinic develops AI tool that can spot 9 dementia types with a single scan
Google DeepMind’s AlphaGenome AI predicts how non-coding DNA can drive disease
Top 10 drugs by patent volume: How biologics build ‘platform empires’ while small molecule create ‘patent thickets’
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE